S4 (Andarine, GTx‑007)
Experimental SARM that can cause yellow-tinted vision and night blindness; never approved as a medicine, with few studies in humans.


The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
LGD-4033 vs S23 vs S4DETAILED OVERVIEW
What is S4 (Andarine, GTx-007)?
S4 (Andarine, GTx-007) is an experimental compound, one of the non-steroidal substances called SARMs, which trigger male-hormone-like effects in muscle and bone. GTx Inc. studied it for an enlarged prostate and for cachexia (severe wasting with weight loss) but moved on to another compound, and it was never approved as a medicine. Only a few small studies have been done in humans. Bodybuilders mention it as a fat-loss aid, without proof.
Its characteristic side effect is a vision disturbance: according to user reports, yellow-tinted vision is very common, and at higher doses night blindness can also appear. Both go away within weeks of stopping. It lowers the body’s own testosterone production, may reduce HDL cholesterol, and liver damage can occur. In women it can cause masculinization that may be partly permanent. It must not be used in pregnancy or breastfeeding, because it can masculinize the fetus. It is banned in competitive sport year-round.
Mechanism
Androgen receptor modulator; also binds light-sensing proteins in the eye
Anabolic activity (Gao 2005)
In rat bioassay anabolic activity ~60-70% Test-level (in vivo)
Half-life
About 4 hours (oral; short)
Onset
1-2 weeks
Legal status
Never an Rx (GTx deprioritized after Phase II in 2010). UGL 'research chemical'. WADA-banned S1.2.
No anecdote collected yet.
Data console
Lab data
Kearbey JD, Wu D, Gao W, Miller DD, Dalton JT . Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.. Xenobiotica.
Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT . The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators.. J Pharmacol Exp Ther.
Marhefka CA, Gao W, Chung K, Bell W, Wu D, Yang HM, Joseph JT, Bohl C, Mustafa S, Miller DD, Dalton JT . Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators.. J Med Chem.
Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Goyal A, Sodeman T, Anwar N . Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature.. Cureus.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R . LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.. Cureus.
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Dose-dependent yellow tint vision: blue-light perception dulls and the color palette shifts toward yellow-green. Reported by roughly 30% of users at 50+ mg/day (retinal opsin binding, Marhefka 2004).
- Night blindness at high doses (>75 mg/day) in roughly 10-20% of users, due to rod-opsin involvement and reduced low-light vision. Reversible within 4-6 weeks after discontinuation.
- HPTA suppression (lowered endogenous testosterone, LH/FSH): milder than with LGD-4033 or RAD-140 because of the short (~4 h) half-life, but not zero, PCT is usually needed.
- Adverse lipid shift: drop in HDL cholesterol, typical of the SARM class. Lipid disturbance is moderate on S4 but should be monitored.
- Hepatotoxicity (liver injury): moderate, milder than with RAD/LGD due to faster reactive-metabolite clearance from the short half-life, but not zero, SARM-associated drug-induced liver injury (DILI) is documented with S4 too.
- Virilization in women at higher doses: voice deepening, increased hair growth, acne, menstrual disruption. Some androgenic effects (e.g. voice changes) can be permanent.
- Compliance and daily-fluctuation risk: the short (~4 h) half-life requires 2-3 doses per day, missed doses cause unstable effect and unpredictable onset of side effects.
Contraindications · 7
- Pre-existing eye disease or visual disorder (glaucoma, retinopathy, retinal/opsin involvement): absolute contraindication because of S4's retinal opsin-binding visual side effect.
- Occupations where night vision is critical (driver, pilot, machine operator): the risk of night blindness and yellow vision creates an accident hazard.
- Pregnancy and breastfeeding: androgenic activity can cause fetal virilization, absolutely to be avoided.
- Planned fatherhood or existing subfertility: HPTA suppression transiently impairs spermatogenesis, recovery can take 2-3 months.
- Pre-existing liver disease or elevated liver enzymes: increases the risk of SARM-associated hepatotoxicity.
- Competitive sport under WADA rules: S4 is banned year-round (S1.2), detectable in urine for 1-2 weeks, the faster clearance offers no hiding place.
- Dyslipidemia or cardiovascular risk: the HDL drop worsens the lipid profile, increased monitoring or avoidance is warranted.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator.
Kearbey JD, Wu D, Gao W, Miller DD, Dalton JT
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators.
Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators.
Marhefka CA, Gao W, Chung K, Bell W, Wu D, Yang HM, Joseph JT, Bohl C, Mustafa S, Miller DD, Dalton JT
Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature.
Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Goyal A, Sodeman T, Anwar N
LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults.
Labban H, Kwait B, Paracha A, Khan A, Singh M, Lopez R
Telegram
Have a question about S4 (Andarine, GTx‑007)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.